Drug Trial Radar · NCT00111722
Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072)
Last checked: Nov 19, 2026Latest source record: Aug 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
393
Actual
Start
May 27, 2005
Primary completion
Feb 15, 2006
Study completion Feb 23, 2006
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- May 25, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test the effectiveness of a marketed drug in the treatment of a menstrual migraine attack.
Conditions
- Migraine
Interventions
MK0462, rizatriptan benzoate / Duration of Treatment -1dayDrug
Comparator: placebo / Duration of Treatment - 1 dayDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients with 2 hour pain relief: 4-point headache severity scale as recorded in patient diary
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.